Syndecan-1 is the main syndecan on the basolateral surface of epithelial cells in adult tissues, it is transiently expressed by mesenchymal cells during development, and it is also found in distinct stages of differentiation of lymphoid cells [1]. Syndecan-2 is present primarily on cells of mesenchymal origin [8], syndecan-3 is primarily expressed by neuronal tissue and cartilage [9, 10], and syndecan-4 is ubiquitously found in most tissues [11, 12]. Syndecan-1, a cell surface heparan sulfate proteoglycan, is critically involved in the differentiation and prognosis of various tumors. In this review, we highlight the synthesis, cellular interactions, and the signalling pathways regulated by syndecan-1. The basal syndecan-1 level is also crucial for understanding the sequential changes involving malignant transformation, tumor progression, and advanced or disseminated cancer stages. Moreover, we focus on the cellular localization of this proteoglycan as cell membrane anchored and/or shed, soluble syndecan-1 with stromal or nuclear accumulation and how this may carry different, highly tissue specific prognostic information for individual tumor types.
of the endoplasmic reticulum. HS biosynthesis occurs in the Golgi apparatus and involves the participation of several enzymes that catalyze the elongation of the disaccharides [20]. The formed polysaccharide chains are further modified by epimerization, deacetylation, and addition of sulfate groups at different positions by the action of several other enzymes such as epimerases and sulfotransferases. Finally, the PGs are delivered by exocytosis to the cell surface [21, 22].

The GAG chains are covalently attached to the core protein in the syndecan-1 via common linkage tetrasaccharides: a serine on the protein core is linked by xylosyl transferases to a xylose on the GAG chain, which is in sequence attached to two galactose residues and one glucuronic acid residue. Acidic amino acids surrounding these Ser-Gly repeats promote substitution with HS as well, possibly by helping the first N-acetylglucosamine (GlcNAc) transferase to act on the linkage sequence [23, 24].

HS consists of repeating disaccharide units of N-acetylgalactosamine (GalNAc) with glucuronic acid (GlcA) or GlcNAc with iduronic acid (IdoA), whereas chondroitin sulfate is composed of disaccharide units of N-acetylgalactosamine (GalNAc) and GlcA [23, 25]. This implies 50–200 negatively charged disaccharide units in each GAG chain due to the attached sulfate groups [26] which can bind a large number of positively charged molecules. Moreover, because of this negative charge, GAG chains are pushed from each other and expand into extracellular space to increase the area of their interaction [27].

Modulation of syndecan-1 initiates a significant alteration in the expression of enzymes involved in HS biosynthesis, metabolism, and turnover, particularly SULFs [28], the enzymes responsible for selective removal of 6-O sulfate groups from HS chains. Since the ability of syndecan-1 to bind growth factors and initiate signaling is dependent on the amount, position, and the orientation of the sulfate groups on the HS chains [29–34], the modulation of these enzymes by syndecan-1 might represent an important feedback mechanism. Experimental data also suggest that syndecan-1 coordinates the expression of various proteoglycans in different tumor types, although the effect varies largely from one tissue type to other [32, 35, 36]. These alterations might lead to modifications of the HS pool of the cells, ultimately modulating the effects of syndecan-1 on signaling.

2.1. The Role of Glycosaminoglycan Chains. GAG chains bind various protein ligands in a structure-dependent manner, but depending on the core protein, their position will be different. The ligand binding to proteoglycans is extremely complex because proteoglycans carry multiple GAG chains that may function cooperatively. Furthermore, cooperation between the core protein and attached GAG chains may also occur. Syndecan-1 exerts its functions predominantly through its HS chains, by binding various morphogens and growth factors with varying affinity to high and low sulfated regions [37, 38]. The extent to which HS is sulfated can vary depending on tissues and cell type, which also has consequences for the functionality of HSPGs in any given tissue. Ligand binding to mature HS is also affected at the cell surface by the two sulfatases (SULF-1 and SULF-2) and heparanases [20].

Syndecan-1 acts as a coreceptor by simultaneously binding various growth factors such as fibroblast growth factors (FGFs), vascular endothelial growth factor (VEGF), Wnt, hepatocyte growth factor (HGF), and their receptors through its HS chains [17, 39–41], thereby stabilizing the growth factor/growth factor receptor complexes. This is followed by activation of downstream tyrosine kinase pathways. Syndecan-1 facilitates the FGFR2-FGFR1 complex formation in different tumor types, comprising lymphomas [42], breast cancer [43], and prostate cancer [29]. It also promotes HGF-induced signaling in myeloma through its receptor MET and downstream activation of Ras/PI3/Akt signaling pathways, resulting in enhanced cell proliferation and survival [30]. WNT1 signaling and tumor growth are enhanced by syndecan-1 in mammary gland tumors [39], and syndecan-1 has a role in the ability of Wnt1 to induce the accumulation of mammary progenitor cells [31]. We have recently shown that syndecan-1 influences multiple signaling pathways in malignant mesothelioma, a highly aggressive mesenchymal tumor. Several growth factors (epithelial growth factor (EGF), platelet-derived growth factor (PDGF), and FGF) and their receptors were finely tuned by syndecan-1. Moreover, these effects go beyond the capacity of syndecan-1 to bind cell-surface receptors, as the expression of downstream effectors was also influenced, often at much higher extent than the syndecan-1 itself, involving ERK/MAPK, Akt, and p38/MAPK signaling cascades and MYC, JNK, JUN, and ETS-1 expression as downstream transcription factors [32]. The delicate control of multiple signaling pathways regulated by syndecan-1 might imply feedback loops and/or epigenetic regulatory mechanisms that collectively affect gene transcription. In contrast, ETS-1 and syndecan-1 are inversely correlated in colon carcinoma [33], pointing toward the cell type specificity of the effect of syndecan-1.

Considerable attention has been focused also on interactions between syndecan HS chains and numerous bioactive molecules such as chemokines and other extracellular matrix (ECM) components [44]. GAG chains interact with chemokines such as CCL2 (MCP-1), CCL5 (RANTES), CXCL12 (SDF-1), and induces chemotaxis of various cells in a chain length- and sulfation pattern-dependent manner [45, 46].

2.2. The Role of the Core Protein. The first evidence that the syndecan-1 core protein has biological function came from studies on mouse mammary tumor cells, where a truncated mutant of syndecan-1 lacking both the transmembrane and cytoplasmic domains was shown to be secreted into the culture medium as soluble glycanated syndecan ectodomain [47].

The HS chains on syndecan-1 are not always required for the initiation of a signaling event, especially for cytoskeletal signaling. Recent discoveries indicate that syndecan-1 core proteins also have biological functions and can modulate cell behavior independent of HS. These regulatory sequences have been proposed to act with both autocrine and paracrine
mechanism and could well represent novel targets for therapeutic interventions, particularly in diseases such as cancer [48].

2.2.1. Extracellular Domain. The syndecan-1 core protein binds via the extracellular domain to both αvβ3 and αvβ5 integrin during angiogenesis or with αvβ1 integrin during reepithelialization of lung tissue, thus potentially forming ternary complexes between extracellular molecules, a cell surface receptor, and a PG component, similar to the ones well recognized for growth factors, their corresponding receptors, and HS chains [6, 49–51]. Similarly, syndecan-1 activates the αvβ3 integrin by binding the insulin-like growth factor-1 receptor (IGF1-R) and integrins directly via its ectodomain, assembling in a ternary receptor complex. It was demonstrated that activation of integrin does not require the other regions of syndecan-1 core protein (cytoplasmic or transmembrane domain) or the HS chains or their attachment sites [5, 52]. Since normal epithelial cells do not express these integrins but in most carcinomas they are upregulated, the syndecan-1-coupled ternary receptor complex is present mostly in tumors. This association between syndecan-1 and αvβ3 and αvβ5 integrins was described for carcinomas [52, 53], myeloma [17], fibroblasts [54], and activated vascular endothelial cells [55].

Syndecans can trigger signaling leading to cell adhesion and spreading either by exposing binding sites on fibronectin for β1 integrin engagement or by modulating the activation state of the β1 integrin [56].

2.2.2. Transmembrane and Cytoplasmic Domains. The transmembrane and cytoplasmic domains of syndecans do not have intrinsic kinase or catalytic activity by themselves and, however, by multimerization or interaction with different intracellular components like GTPases or kinases play an important role in propagating the signal transduction [57]. The conserved GGLVG transmembrane domain of syndecan-1 mediates dimerization [58, 59]. Usually, this occurs in lipid rafts, the parts of the plasma membranes containing combinations of glycosphingolipids and cholesterol [60]. Lipid rafts are essential for receptor binding and signal transduction from the cell surface into the cell. The conserved motif GGLVG is also necessary for retaining cholesterol in the membrane [58]. Decreasing the cholesterol level in the lipid rafts leads to their degradation and to the damage of the signaling cascade [61].

The short cytoplasmic domain of syndecan-1 interacts with a number of cytosolic proteins and plays a role in endocytosis. It has two conserved C1 and C2 sites that flank the variable region V. The conserved C1 site mediates syndecan dimerization and interacts with numerous intracellular proteins such as ezrin, tubulin, and cortactin that regulate the organization of the cytoskeleton [62, 63]. The conserved C2 domain (EFYA) binds to PDZ-binding proteins, such as synbindin, synectin, CASK [64], CASK/LIN-2, and syntentin that play an important role in vesicular transportation, adhesion, synaptic signaling, neuronal migration, and metastasis formation [65–67]. The cytoplasmic domain of syndecan-1 also interacts with αvβ3 integrin and regulates activation of ErbB2 by the integrin [68].

3. Shedding of the Extracellular Domain and Its Role in Signaling

Syndecans can be found in two forms: membrane-incorporated and soluble. The soluble form is the ectodomain containing GAG chains that have been shed from the cell surface. The proteolysis of syndecan-1 occurs at a specific juxtamembrane cleavage site between amino acids A243 and S244 [69] and is performed by a number of matrix metalloproteinases: MMP7 [49], MMP9 [70], MMP14 [71], the membrane-associated MT-MMP1, ADAM10, and ADAM17, and other sheddases.

The shedding is regulated by a large number of extracellular stimulatory agents: growth factors, chemokines, trypsin, heparanase, bacterial virulence factors, insulin, and cellular stress [72, 73]. Among growth factors, FGF-2 was shown to activate MMP-7 mediated shedding [74]. Heparanase accelerates MMP-9 mediated shedding of syndecan-1 in both myeloma and breast cancer [17]. The heparanase mediated syndecan-1 shedding occurs through upregulation of ERK phosphorylation that leads to enhanced expression of MMP-9 [75, 76]. Recent studies also show that heparanase induced shedding stimulates the expression of the active protease and through this stimulates tumor growth and spreading [75, 77]. Even though syndecan-1 shedding can occur constitutively, shedding is induced and accelerated in tumors, following the activation of both G-protein coupled receptors and protein tyrosine kinases by specific agonists, including thrombin and epidermal growth factor [78]. Certain signal transducers, such as protein kinase C and nuclear transcription factor NF-kB, also influence the shedding of ectodomain [26]. Interestingly, syndecan-1 can itself participate in regulation of metalloproteinases as the HS chains on the core protein suppresses the shedding [73]. In addition, interaction of cytoplasmic domain with Rab5 affects shedding of ectodomain [79] and the phosphorylation of tyrosines in the conserved sites of the cytoplasmic domain initiates the shedding of the ectodomain [80, 81].

Chemotherapy can also induce shedding of syndecan-1 in malignant myeloma, predominantly via ADAMs, and this shed syndecan-1 is functionally active, leading to relapse and formation of a more aggressive phenotype [82]. On the other hand, in colorectal cancer shed syndecan-1 induces resistance to chemotherapy via the EGFR pathway [83].

The shedding of syndecan-1 has biological significance, as the shed ectodomain contains the intact HS chains, retaining its ability to bind growth factors and other ECM components, creating a chemotactic gradient. Shed ectodomain can also compete with the membrane-bound syndecan-1 for ligand binding, and it can sequester the HS binding factors in the extracellular matrix and thereby modulate their biological functions [84]. Moreover, shed syndecan-1 is able to deliver growth factors to other cells, as it was shown for syndecan-1 originating from multiple myeloma cells, which is released in the medium and is taken up by the surrounding stromal...
cells [85]. As a consequence, membrane-bound and soluble syndecan-1 can have opposite effects on cancer cells and can influence a wide range of behaviors such as tumor growth and metastasis, chemokine localization, leukocyte trafficking, and pathogen virulence. Thus, the change in localization of syndecan-1 from the cell surface to the extracellular matrix has distinct and important pathological effects. This was experimentally verified by a number of studies. For example, in breast cancer overexpression of wild type syndecan-1 increased proliferation, but overexpression of constitutively shed syndecan-1 inhibited it [86]. Heparanase mediated shedding of syndecan-1 correlates with enhancement of both VEGF [17] and HGF [87] signaling and affects angiogenesis. It was also shown that shed syndecan-1 and predominantly its HS chains from stromal fibroblasts were required for breast was also shown that shed syndecan-1 and predominantly its HS chains from stromal fibroblasts were required for breast

4. The Role of Syndecan-1 in Epithelial-Mesenchymal Transition and Malignant Transformation

During malignant transformation, cancer progression and metastasis normal epithelial cells undergo multiple orchestrated molecular and morphological changes leading to mesenchymal characteristics and migratory phenotype. One of the initial central steps in this epithelial-mesenchymal transition (EMT) [89, 90] is the transcriptional repression of epithelial markers, resulting in simultaneous loss of E-cadherin and syndecan-1 [91, 92]. Depletion of epithelial cells of cell surface syndecan-1 profoundly alters their morphology and anchorage-dependent growth [91], syndecan-1 thus being necessary to maintain the epithelial phenotype. Transforming growth factor-beta (TGF-β) can induce EMT in various cell types, and it appear to be responsible for the activation of a spectrum of EMT inducing transcription factors [90]. Among these SNAIL has been shown to repress the expression of syndecan-1 [93].

A coordinated loss of syndecan-1 and E-cadherin has been documented in many epithelial malignancies compared to their benign counterparts. Sequential loss or decreased expression of both these adhesion molecules was observed in skin associated with malignant transformation and their expression was further diminished with decreasing cell differentiation in invasive squamous cell carcinoma [94]. A significant reduction of both syndecan-1 and E-cadherin expression was also seen in severely dysplastic epithelium as compared to moderate dysplasia in colorectal-adenoma, with further reduction of both molecules in carcinomas compared to adenomas [33, 95]. In prostate syndecan-1 was expressed in basolateral surface of normal epithelium, changing to a granular cytoplasmic expression pattern in carcinomas [96], a switch in subcellular expression pattern linked to EMT.

5. Nuclear Localization of Syndecan-1

Though syndecan-1 is referred to as a membrane-bound protein, it has been detected in the nuclear compartment in different cell types [97, 98]. The presence and functions of heparan sulfate in the nucleus are a known phenomenon but the translocation of the core protein of the proteoglycan itself is relatively less studied. The concept of nuclear translocation of syndecan-1 was reinforced by the identification of the nuclear localization signals (NLS) at the cytoplasmic tail of the PG, explaining the mechanism of nuclear translocation. Syndecan-1 enters the cell membrane via raft dependent or receptor mediated endocytosis. The MKKK sequence is essential for the internalization by raft-dependent endocytosis [99] and the RMKKK motif is the minimal sequence required for its nuclear localization [100]. The complete route of syndecan-1 internalization is not yet elucidated, but it is known that the nuclear translocation of syndecan-1 is tubulin-dependent [97]. It has been shown that the full-length form of the syndecan-1 molecule (containing the ectodomain, transmembrane, and cytoplasmic domains) can translocate to the nucleus. Recent studies show that the shed syndecan-1 also translocates to the nucleus of both tumor cells and bone-marrow-derived stromal cells [101]. The RMKKK sequence is found within the cytoplasmic domain of syndecan-1 and thus is not present in the shed molecule. This indicates that shed syndecan-1 enters the nucleus via an alternative mechanism. Exogenously added HS chains or the syndecan-1 ectodomain with its heparan sulfate chains could enter the nucleus as well [102]. For the nuclear translocation of the shed syndecan-1 sulfated HS chains of the PG and an unknown cargo (possibly a heparan sulfate-binding growth factor) bound to these heparan sulfate chains are required. This cargo remains bound to the shed syndecan-1 even after its translocation to the nucleus [85]. Its removal from shed syndecan-1 prevented the translocation to the nucleus, so it was hypothesized that this HS binding growth factor contains nuclear localization sequences [85].

The nuclear HS regulates gene expression by several mechanisms. First, it regulates the transcription machinery by inhibiting DNA topoisomerase, thereby preventing relaxation of DNA and the accessibility of transcription factors [103]. Moreover, HS inhibits transcription factors [104, 105] probably directly binding to them, as their DNA binding domain contains high affinity heparin binding sequences [106]. The nuclear HS can also regulate gene expression by modulating the acetylation status of histone proteins. Both nuclear syndecan-1 [101] and HS chains [102] inhibit nuclear histone acetyl-transferase activity and acetylation of histones thereby decreasing gene expression that drive tumor progression [101].

Transport of growth factors into the nucleus is another possible function of HS, as the heparin-binding growth factors and other macromolecules are internalized through
HSPGs [100, 107–111]. This was shown in case of syndecan-1 for HGF [85] or FGFR2 [107], with this latter colocalizing in the nucleus [100]. Other ligands, morphogens, peptides, and exosomes can also follow the same routes for entering the nucleus [110, 112, 113].

Nuclear HS has antiproliferative effects [106, 114, 115] and the extent of the growth inhibition depends on cell confluence, the composition, and sulfation grade of the nuclear HS [106] and it also varies in malignant and benign cells [116, 117]. Particularly, the highly sulfated HS chains present in the nucleus were shown to inhibit proliferation. Interestingly, with increasing cell confluence, the sulfation level also increases. In malignant mesothelioma cells, TGFβ inhibited the nuclear translocation of syndecan-1 in parallel with an antiproliferative effect [118]. There seems to be a correlation between nuclear HS and cell cycle progression also, though the exact mechanisms of action and the cause-effect relationship are not established yet. The nuclear entry of HS depends on certain cell-cycle phases [97] and cell cycle progression is regulated by the amount of nuclear HS or HSPG [35, 97, 117, 119–121], but in contrary, mitotic cells loose nuclear HS [106] and induced cell-cycle arrest inhibits nuclear translocation [100].

6. Syndecan-1 in Cancer: Differentiation Marker with Prognostic Value

Several studies demonstrate that syndecan-1 expression in cancer is significantly correlated with tumor cell differentiation and prognosis. The basal syndecan-1 level and its cellular localization are however crucial for understanding the sequential changes involving malignant transformation, tumor progression, and advanced or disseminated cancer stages. Consequently cell-membrane bound, stromal, and soluble shed syndecan-1 seem to carry different, highly tissue specific information for individual tumor types that has to be viewed as contributing parts of a whole spectrum [Table 1].

Experimental overexpression of full length syndecan-1 enhances cell-ECM cohesion and restricts cell migration, whereas the loss of the syndecan-1 ectodomain from the cell surface increases the migratory capacity of tumor cells [122]. Similarly, overexpression of the full-length syndecan-1 enhances fibrosarcoma cell adhesion, while constructs lacking the ectodomain inhibit adhesion [121]. In a breast cancer cell line overexpression of wild type syndecan-1 increased cell proliferation, whereas overexpression of constitutively shed syndecan-1 had the opposite effect [86]. Presence of syndecan-1 is associated with favorable outcome in lung cancer and mesothelioma [123, 124], but it can also promote the growth of other tumor types [125, 126]. Moreover, different research groups found either tumor promoting or tumor-inhibiting effects in the same tumor type, such as in colorectal cancer [127, 128] or prostate cancer [93, 125]. These seemingly contradictory data might partly be resolved by considering the localization of syndecan-1 in addition to its expression level.

The expression of cell surface syndecan-1 in tumor tissue is context-specific. For instance, compared to normal epithelial cells, decreased syndecan-1 expression has been found during malignant transformation of prostate cancer [93], and reduced cell-membrane syndecan-1 immunoreactivity was observed in many epithelial malignancies connected to various stages of tumor progression.

Syndecan-1 present in the stromal component of different malignant tumors generally indicates poor prognosis through promotion of tumor cell invasion and development of metastasis [129, 130] and it also might stimulate the growth of epithelial cells [131, 132]. Also high level of soluble syndecan-1 generally associates with poor prognosis and it correlates to tumor burden, cancer invasiveness, and risk for metastasis.

6.1. Tumors of the Lung and Pleura. In malignant mesothelioma, syndecan-1 levels are generally low. Presence of syndecan-1 is related to differentiation state of mesothelioma cells. It is mainly present in epithelial phenotype and in the epithelial component of biphasic mesotheliomas and it correlates with favorable prognosis [124]. Generally adenocarcinomas show higher cell surface and soluble syndecan-1 levels than mesotheliomas [135, 171, 172], the latter indicating worse prognosis. Considering this, syndecan-1 was proposed as a putative diagnostic marker in distinguishing mesotheliomas from metastatic adenocarcinomas. In squamous cell lung carcinoma low cell surface syndecan-1 expression is associated with unfavorable outcome [123] and the majority of NSCLC express varying syndecan-1 reactivity by immunohistochemistry of tumor tissue. High serum syndecan-1 levels associate with poor outcome in both NSCLC and SCLC [133, 134, 173, 174].

6.2. Head- and Neck Carcinoma. Decreased syndecan-1 expression in epithelial cells is associated with tumor aggressiveness and poor survival in squamous cell head and neck carcinoma [137–139, 142]. Thus, the level of the syndecan-1 expression can be a novel prognostic factor in head and neck cancers [140]. In squamous oral carcinoma stromal syndecan-1 inversely correlates with tumor grade and invasiveness [137]. In the serum of larynx and hypopharynx carcinoma patients the soluble syndecan-1 levels decrease after surgery and/or radiotherapy and the levels may increase at the time of tumor recurrence. The reason for this could be that a part of soluble syndecan-1 originates from the tumor tissue. The low syndecan-1 serum level in these tumors was predictive for favorable outcome [141]. Syndecan-1 is uncommonly expressed in nasopharyngeal carcinoma samples, but its expression correlates with advanced clinical stages and poor outcome [143].

6.3. Gastrointestinal Malignancies. The expression of syndecan-1 is induced in the stroma of gastric cancer, where its presence correlates with poor prognosis. Epithelial expression of syndecan-1 negatively correlates with lymph node metastasis [144] and associates with a longer survival, whereas stromal syndecan-1 expression associates with a shorter survival [145]. Low expression of syndecan-1 significantly correlates with the invasion and metastasis of gastric carcinoma [146].
Syndecan-1 shedding is increased in colorectal cancer [83] and the loss of epithelial syndecan-1 is associated with advanced clinical stage and poor prognosis [128, 148]. Selective expression of syndecan-1 in tumor-initiating cell lines suggests a role of syndecan-1 for cancer stem-cells [149]. On the other hand, there are studies showing that syndecan-1 immunopositivity is associated with tumor size [127].

Syndecan-1 is expressed in human normal liver [175] and the loss of syndecan-1 expression is a typical feature of hepatocellular carcinoma with high metastatic potential, where syndecan-1 expression is reduced both at mRNA and at protein levels [150].

Syndecan-1 expression is heterogenous and variable in intensity and distribution in intrahepatic cholangiocarcinoma. Higher level of syndecan-1 in neoplastic cells is associated with inhibition of invasiveness in vitro. Reduced expression of syndecan-1 is correlated with poor histological differentiation, lymph node metastasis, and poor prognosis after surgical resection [176].

In pancreatic cancer [151] increased levels of membrane syndecan-1 were found. In this tumor type stromal syndecan-1 expression is an independent prognostic marker, whereas epithelial syndecan-1 expression predicts better prognosis only in resectable tumors [177].

### 6.4. Breast Cancer

Breast cancer is associated with increased cell-membrane syndecan-1 [154]. Its expression is also induced in the stromal cells adjacent to the cancer, particularly in tumors exhibiting an aggressive phenotype [152]. The loss of epithelial syndecan-1 correlated with the syndecan-1 stromal expression and is found to be a significant poor prognostic factor [153]. Studies from an in vitro breast cancer model have also suggested that syndecan-1 directly participates in tumor cell spreading and adhesion [14]. Syndecan-1 expression is induced in the stroma of invasive breast carcinomas in some cases [155], whereas other studies linked an unfavorable prognosis in breast carcinoma patients with

**Table 1: Prognostic significance of syndecan-1 in relation to its cellular localization.**

| Intrathoracic cancers | Soluble syndecan-1 | Cell Surface syndecan-1 | References |
|-----------------------|-------------------|-------------------------|------------|
| Lung                  | Unfavorable       | Favorable               | [91, 123, 124, 133, 134] |
| Mesothelioma          | Unfavorable       | Favorable               | [124, 135]  |

**Skin cancers**

| Basal cell carcinoma | Favorable         | [136] |
| Squamous cell carcinoma (oral and cutaneous) | Favorable | Favorable | [94, 137] |

**Head and neck cancers**

| Head and neck | Favorable | [129, 138–140] |
| Laryngeal, hypopharynx | Unfavorable | Unfavorable | [141] |
| Nasopharyngeal | Inconclusive* | [142, 143] |

**Gastrointestinal cancers**

| Gastric | Unfavorable | Favorable | [144–147] |
| Colorectal | Unfavorable | Inconclusive* | [127, 128, 148, 149] |
| Hepatocellular | Favorable | Favorable | [150] |
| Pancreatic | Unfavorable | Inconclusive* | [151] |

**Breast cancer**

| Breast cancer | Inconclusive* | Inconclusive* | [131, 152–157] |

**Urogenital cancers**

| Cervical | Favorable | [158] |
| Ovarial | Unfavorable | Unfavorable | [159] |
| Endometrial | Unfavorable | Inconclusive* | [126, 160] |
| Prostate | Unfavorable | Inconclusive* | [93, 125, 161] |
| Bladder | Unfavorable | Unfavorable | Favorable | [162, 163] |
| Urothelial | Unfavorable | | [164] |

**Hematological malignancies**

| Myeloma | Unfavorable | [165–168] |
| Hodgkin’s lymphoma | Unfavorable | [169] |

**Other cancers**

| Thyroid | Unfavorable | Unfavorable | [130] |
| Liposarcoma | Unfavorable | | [170] |

* denotes inconclusive results, where different studies show opposite prognosis.
syndecan-1 in tumor cells but a better prognosis for those lacking syndecan-1 expression within the stroma. Furthermore, epithelial syndecan-1 expression was associated with negative ER status, whereas stromal syndecan-1 expression was associated with positive ER status [156]. A recent study showed that the proportion of syndecan-1 positive cells correlated with tumor grade better than the amounts demonstrated by immunohistochemistry, nuclear grade, and localization of syndecan-1. The estrogen and progesterone receptors both correlated negatively with syndecan-1 staining [157].

6.5. Urogenital Cancers. Syndecan-1 promotes the growth and invasive/metastatic potential of endometrial tumors. Upregulation of syndecan-1 in a xenograft model leads to the development of proliferative and invasive/metastatic phenotypes in endometrial cancer. The growth advantage conferred by syndecan-1 overexpression was accompanied by increased tumor angiogenesis. Syndecan-1 seems to be early in the signal cascades necessary for the onset of endometrial cancer progression [126]. Loss of epithelial syndecan-1 expression and induction of stromal syndecan-1 expression are associated with reduced survival in patients with endometrial cancer [160]. Increased syndecan-1 staining was a poor prognostic factor for survival also in ovarian cancer, where syndecan-1 was also present in the stromal compartment [159].

In prostate cancer the syndecan-1 level is correlated inversely with tumor grade [93]. In normal prostate tissue syndecan-1 is expressed mainly by epithelial cells while in tumors an overall increase of syndecan-1 expression was observed in the tumor stroma along with its disappearance from tumor epithelial cells [161]. In tumor initiating cells and mouse model in contrary, it was found that syndecan-1 immunopositivity is associated with recurrence and it has a role in maintaining tumor stem cells [125]. Syndecan-1 expression has a prognostic value also in bladder cancer. Surface expression of syndecan-1 was inversely correlated with tumor stage in primary nonmuscle-invasive bladder cancer [162], while high stromal syndecan-1 was associated with poor prognosis [163]. Syndecan-1 is also present in the stroma of urothelial cancer indicating a possible use as clinically important diagnostic marker [164].

6.6. Hematological and Other Malignancies. Syndecan-1 is the main diagnostic and prognostic marker of myeloma, and its importance for hematological malignancies was recently reviewed [178]. It is present in the nucleus of myeloma cells, and amount of nuclear syndecan-1 is reduced upon elevation of heparanase expression. Increased levels of shed syndecan-1 in serum correlate to tumor burden and poor outcome in multiple myeloma [165]. The levels of syndecan-1 were higher also in Hodgkin lymphoma patients than controls [179]. Positive expression of syndecan-1 was found in the plasma cells in B-CLL [180].

Expression of syndecan-1 was found in malignant glioma cells [181] and is highly overexpressed in dedifferentiated liposarcoma [170].

7. Conclusion

Taken together, the multitude and diversity of molecular functions related to syndecan-1 and its different localization highlights a complex tissue specific and development related expression pattern that is perturbed in many tumors. Several studies support the idea that there is a complementary feature in cell surface, soluble, stromal, and nuclear localization patterns but simultaneous detection of these parameters is very sparse. This gives a fragmentary description of the syndecan-1 expression and isolated expression levels have to be expanded to cover the whole spectrum of localizations in an effort to push further our understanding of the plethora of molecular events connected to syndecan-1.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] S. Saunders, M. Jalkanen, S. O’Farrell, and M. Bernfield, “Molecular cloning of syndecan, an integral membrane proteoglycan,” The Journal of Cell Biology, vol. 108, no. 4, pp. 1547-1556, 1989.

[2] M. Bernfield, M. Götte, P. W. Park et al., “Functions of cell surface heparan sulfate proteoglycans,” Annual Review of Biochemistry, vol. 68, pp. 729–777, 1999.

[3] R. Chakravarti and J. C. Adams, “Comparative genomics of the syndecans defines an ancestral genomic context associated with matrilins in vertebrates,” BMC Genomics, vol. 7, article 83, 2006.

[4] L. Chen, J. R. Couchman, J. Smith, and A. Woods, “Molecular characterization of chicken syndecan-2 proteoglycan,” Biochemical Journal, vol. 366, no. 2, pp. 481–490, 2002.

[5] D. M. Beauvais, B. J. Burbach, and A. C. Rapraeger, “The syndecan-1 ectodomain regulates αvβ3 integrin activity in human mammary carcinoma cells,” The Journal of Cell Biology, vol. 167, no. 1, pp. 171–181, 2004.

[6] D. M. Beauvais, B. J. Ell, A. R. McWhorter, and A. C. Rapraeger, “Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor,” Journal of Experimental Medicine, vol. 206, no. 3, pp. 691–705, 2009.

[7] R. Kokenyesi and M. Bernfield, “Core protein structure and sequence determine the site and presence of heparan sulfate and chondroitin sulfate on syndecan-1,” The Journal of Biological Chemistry, vol. 269, no. 16, pp. 12304–12309, 1994.

[8] P. Marynen, J. Zhang, J.-J. Cassiman, H. Van den Berghe, and G. David, “Partial primary structure of the 48- and 90-kilodalton core proteins of cell surface-associated heparan sulfate proteoglycans of lung fibroblasts. Prediction of an integral membrane domain and evidence for multiple distinct core proteins at the cell surface of human lung fibroblasts,” The Journal of Biological Chemistry, vol. 264, no. 12, pp. 7017–7024, 1989.

[9] D. J. Carey, D. M. Evans, R. C. Stahl et al., “Molecular cloning and characterization of N-syndecan, a novel transmembrane heparan sulfate proteoglycan,” The Journal of Cell Biology, vol. 117, no. 1, pp. 191–201, 1992.

[10] S. E. Gould, W. B. Upholt, and R. A. Kosher, “Syndecan 3: a member of the syndecan family of membrane-intercalated
proteoglycans that is expressed in high amounts at the onset of chicken limb cartilage differentiation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 89, no. 8, pp. 3271–3275, 1992.

[11] G. David, B. van der Schueren, P. Marynen, J.-J. Cassiman, and H. van den Bergh, “Molecular cloning of amphiglycan, a novel integral membrane heparan sulfate proteoglycan expressed by epithelial and fibroblastic cells,” *The Journal of Cell Biology*, vol. 118, no. 4, pp. 961–969, 1992.

[12] T. Kojima, N. W. Shworak, and R. D. Rosenberg, “Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line,” *The Journal of Biological Chemistry*, vol. 267, no. 7, pp. 4870–4877, 1992.

[13] W. Liu, E. D. Litwack, M. J. Stanley, J. K. Langford, A. D. Lander, and R. D. Sanderson, “Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypicans have distinct functions,” *The Journal of Biological Chemistry*, vol. 273, no. 35, pp. 22825–22832, 1998.

[14] D. M. Beaufays and A. C. Rapraeger, “Syndecan-1-mediated cell spreading requires signaling by αvβ3 integrins in human breast carcinoma cells,” *Experimental Cell Research*, vol. 286, no. 2, pp. 219–232, 2003.

[15] H. Lee, Y. Kim, Y. Choi, S. Choi, E. Hong, and E.-S. Oh, “Syndecan-2 cytoplasmic domain regulates colon cancer cell migration via interaction with syntenin-1,” *Biochemical and Biophysical Research Communications*, vol. 409, no. 1, pp. 148–153, 2011.

[16] J.-H. Lee, H. Park, H. Chung et al., “Syndecan-2 regulates the migratory potential of melanoma cells,” *The Journal of Biological Chemistry*, vol. 284, no. 40, pp. 27167–27175, 2009.

[17] A. Purushothaman, T. Uyama, F. Kobayashi et al., “Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis,” *Blood*, vol. 115, no. 12, pp. 2449–2457, 2010.

[18] E. I. Leonova and O. V. Galzitskaya, “Structure and functions of syndecans in vertebrates,” *Biochemistry*, vol. 78, no. 10, pp. 1071–1085, 2013.

[19] E. I. Leonova and O. V. Galzitskaya, “Comparative characteristics of the structure and function for syndecan-1 from animal organisms,” *Molekularnaia Biologiia*, vol. 47, no. 3, pp. 505–512, 2013.

[20] N. Adhikari, M. Carlson, B. Lerman, and J. L. Hall, “Changes in expression of proteoglycan core proteins and heparan sulfate enzymes in the developing and adult murine aorta,” *Journal of Cardiovascular Translational Research*, vol. 4, no. 3, pp. 313–320, 2011.

[21] J. D. Esko and S. B. Selleck, “Order out of chaos: assembly of ligand binding sites in heparan sulfate,” *Annual Review of Biochemistry*, vol. 71, pp. 435–471, 2002.

[22] E. I. Leonova and O. V. Galzitskaya, “Cell communication using intrinsically disordered proteins: what can syndecans say?” *Journal of Biomolecular Structure and Dynamics*, vol. 33, no. 5, pp. 1037–1050, 2015.

[23] L. Zhang, G. David, and J. D. Esko, “Repetitive Ser-Gly sequences enhance heparan sulfate assembly in proteoglycans,” *The Journal of Biological Chemistry*, vol. 270, no. 45, pp. 27127–27135, 1995.

[24] M. Romaris, C. Coomans, H. Ceulemans, A.-M. Bruystens, S. Vekemans, and G. David, “Molecular polymorphism of the syndecans. Identification of a hypo-glycanated murine syndecan-1 splice variant,” *The Journal of Biological Chemistry*, vol. 274, no. 26, pp. 18667–18674, 1999.

[25] N. Maeda, “Proteoglycans and neuronal migration in the cerebral cortex during development and disease,” *Frontiers in Neuroscience*, vol. 9, article 98, 2015.

[26] T. Manon-Jensen, Y. Itoh, and J. R. Couchman, “Proteoglycans in health and disease: the multiple roles of syndecan shedding,” *The FEBBS Journal*, vol. 277, no. 19, pp. 3876–3889, 2010.

[27] C. Iannuzzi, G. Irace, and I. Sirangelo, “The effect of glycosaminoglycans (GAGs) on amyloid aggregation and toxicity,” *Molecules*, vol. 20, no. 2, pp. 2510–2528, 2015.

[28] G. Heidari-Hamedani, R. R. Vivès, A. Seffouh et al., “Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma,” *Cellular Signalling*, vol. 27, no. 10, pp. 2054–2067, 2015.

[29] X. Wu, M. Kan, F. Wang, C. Jin, C. Yu, and W. L. McKeehan, “A rare premalignant prostate tumor epithelial cell syndecan-1 forms a fibroblast growth factor-binding complex with progression-promoting ectopic fibroblast growth factor receptor I,” *Cancer Research*, vol. 61, no. 13, pp. 5295–5302, 2001.

[30] P. W. B. Derksen, D. J. de Gorter, H. P. Meijer et al., “The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma,” *Leukemia*, vol. 17, no. 4, pp. 764–774, 2003.

[31] B. Y. Liu, S. P. McDermott, S. S. Khwaja, and C. M. Alexander, “The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 12, pp. 4158–4163, 2004.

[32] T. Szatmári, F. Mundt, G. Heidari-Hamedani et al., “Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells,” *PLoS ONE*, vol. 7, no. 10, Article ID e48091, 2012.

[33] Z. Pap, Z. Pávai, L. Dénes, I. Kovácszký, and J. Jung, “An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1,” *Pathology and Oncology Research*, vol. 15, no. 4, pp. 579–587, 2009.

[34] M. Kato, H. Wang, M. Bernfield, J. T. Gallagher, and J. E. Turnbull, “Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains,” *The Journal of Biological Chemistry*, vol. 269, no. 29, pp. 18881–18890, 1994.

[35] F. Zong, E. Fthenou, J. Castro et al., “Effect of syndecan-1 overexpression on mesenchymal tumour cell proliferation with focus on different functional domains,” *Cell Proliferation*, vol. 43, no. 1, pp. 29–40, 2010.

[36] B. Péterfia, T. Füle, K. Baghy et al., “Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with Syndecan-2,” *PLoS ONE*, vol. 7, no. 6, Article ID e39474, 2012.

[37] D. J. Carey, “Syndecans: multifunctional cell-surface co-receptors,” *The Biochemical Journal*, vol. 327, no. 1, pp. 1–16, 1997.

[38] S. Tumova, A. Woods, and J. R. Couchman, “Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions,” *The International Journal of Biochemistry and Cell Biology*, vol. 32, no. 3, pp. 269–288, 2000.

[39] C. M. Alexander, F. Reichman, M. T. Hinkes et al., “Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice,” *Nature Genetics*, vol. 25, no. 3, pp. 329–332, 2000.
[40] C. Seidel, M. Borset, O. Hjertner et al., “High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity,” *Blood*, vol. 96, no. 9, pp. 3139–3146, 2000.

[41] G. Su, S. A. Blaine, D. Qiao, and A. Friedl, “Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation,” *Journal of Biological Chemistry*, vol. 282, no. 20, pp. 14906–14915, 2007.

[42] M. S. Fillia, P. Dam, and A. C. Rapraeger, “The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity,” *Journal of Cellular Physiology*, vol. 174, no. 3, pp. 310–321, 1998.

[43] C. Mundhenke, K. Meyer, S. Drew, and A. Friedl, “Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas,” *The American Journal of Pathology*, vol. 160, no. 1, pp. 185–194, 2002.

[44] O. Marin, “Cellular and molecular mechanisms controlling the migration of neocortical interneurons,” *European Journal of Neuroscience*, vol. 38, no. 1, pp. 2009–2029, 2013.

[45] G. S. V. Kuschen, F. Coulin, C. A. Power et al., “Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses,” *Biochemistry*, vol. 38, no. 39, pp. 12959–12968, 1999.

[46] J. Hirose, H. Kawashima, O. Yoshie, K. Tashiro, and M. Miyasaka, “Versican interacts with chemokines and modulates cellular responses,” *The Journal of Biological Chemistry*, vol. 276, no. 7, pp. 5228–5234, 2001.

[47] M. Mali, H. Andtfolk, H. M. Miettinen, and M. Jalkanen, “Suppression of tumor cell growth by syndecan-1 ectodomain,” *The Journal of Biological Chemistry*, vol. 269, no. 45, pp. 27795–27798, 1994.

[48] G. De Rossi and J. R. Whiteford, “Novel insight into the biological functions of syndecan ectodomain core proteins,” *BioFactors*, vol. 39, no. 4, pp. 374–382, 2013.

[49] P. Chen, L. E. Abacherli, S. T. Nadler, Y. Wang, Q. Li, and W. C. Parks, “MMP7 shedding of syndecan-1 facilitates re-epithelialization by affecting αβ integrin activation,” *PLoS ONE*, vol. 4, no. 8, Article ID e6565, 2009.

[50] N. J. Harmer, “Insights into the role of heparan sulphate in fibroblast growth factor signalling,” *Biochemical Society Transactions*, vol. 34, no. 3, pp. 442–445, 2006.

[51] N. Jastrebova, M. Vanwildemeersch, U. Lindahl, and D. Spillmann, “Heparan sulphate domain organization and sulfation modulate FGF-induced cell signalling,” *The Journal of Biological Chemistry*, vol. 285, no. 35, pp. 26842–26851, 2010.

[52] A. C. Rapraeger, “Syntatin: a selective inhibitor of the syndecan-1-coupled 1GFR-alphavbeta3 integrin complex in tumorigenesis and angiogenesis,” *The FBS Journal*, vol. 280, no. 10, pp. 2207–2215, 2013.

[53] D. M. Beauvais and A. C. Rapraeger, “Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation,” *Journal of Cell Science*, vol. 123, no. 21, pp. 3796–3807, 2010.

[54] K. J. McQuade, D. M. Beauvais, B. J. Burbach, and A. C. Rapraeger, “Syndecan-1 regulates alphavbeta5 integrin activity in B82L fibroblasts,” *Journal of Cell Science*, vol. 119, part 12, pp. 2445–2456, 2006.

[55] D. M. Beauvais, B. J. Ell, A. R. McWhorter, and A. C. Rapraeger, “Syndecan-1 regulates αβ and αβ integrin activation during angiogenesis and is blocked by syntatin, a novel peptide inhibitor,” *Journal of Experimental Medicine*, vol. 206, no. 3, pp. 691–705, 2009.

[56] K. Iba, R. Albrechtsen, B. Gilpin et al., “The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to betal integrin-dependent cell spreading,” *The Journal of Cell Biology*, vol. 149, no. 5, pp. 1143–1156, 2000.

[57] K. Lambaerts, S. A. Wilcox-Adelman, and P. Zimmermann, “The signaling mechanisms of syndecan heparan sulfate proteoglycans,” *Current Opinion in Cell Biology*, vol. 21, no. 5, pp. 662–669, 2009.

[58] P. J. Barrett, Y. Song, W. D. Van Horn et al., “The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol,” *Science*, vol. 336, no. 6085, pp. 1168–1171, 2012.

[59] C.-H. Heldin, “Dimerization of cell surface receptors in signal transduction,” *Cell*, vol. 80, no. 2, pp. 213–223, 1995.

[60] K. Simons and E. Ikonen, “Functional rafts in cell membranes,” *Nature*, vol. 387, pp. 6633, pp. 569–572, 1997.

[61] Y. C. Li, M. J. Park, Y.-N. Kim, and Y.-N. Kim, “Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents,” *The American Journal of Pathology*, vol. 168, no. 4, pp. 1107–1118, 2006.

[62] E. Tkachenko, J. M. Rhodes, and M. Simons, “Syndecans: new kids on the signaling block,” *Circulation Research*, vol. 96, no. 5, pp. 488–500, 2005.

[63] I. C. Dew and K. R. MacKenzie, “Transmembrane domains of the syndecan family of growth factor coreceptors display a hierarchy of homotypic and heterotypic interactions,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 52, pp. 20782–20787, 2007.

[64] Y.-P. Hsu and M. Sheng, “Regulated expression and subcellular localization of syndecan heparan sulfate proteoglycans and the syndecan-binding protein CASK/LIN-2 during rat brain development,” *The Journal of Neuroscience*, vol. 19, no. 17, pp. 7415–7425, 1999.

[65] M. Bernfield, R. Kokenyesi, M. Kato et al., “Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans,” *Annual Review of Cell Biology*, vol. 8, pp. 365–393, 1992.

[66] D. J. Carey, K. M. Bendt, and R. C. Stahl, “The cytoplasmic domain of syndecan-1 is required for cytoskeleton association but not detergent insolubility. Identification of essential cytoplasmic domain residues,” *The Journal of Biological Chemistry*, vol. 271, no. 25, pp. 15253–15260, 1996.

[67] J. J. Grootjans, P. Zimmermann, G. Reekmans et al., “Syntenin, a PDZ protein that binds syndecan cytoplasmic domains,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 25, pp. 13683–13688, 1997.

[68] H. Wang, L. Leavitt, R. Ramaswamy, and K. A. Jacks, “Interaction of syndecan and alphavbeta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation,” *The Journal of Biological Chemistry*, vol. 285, no. 18, pp. 13569–13579, 2010.

[69] Z. Wang, M. Götze, M. Bernfield, and O. Reizes, “Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site,” *Biochemistry*, vol. 44, no. 37, pp. 12355–12361, 2005.

[70] S. Brule, N. Charnaux, A. Sutton et al., “The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9,” *Glycobiology*, vol. 16, no. 6, pp. 488–501, 2006.
migration,” *The Journal of Biological Chemistry*, vol. 278, no. 42, pp. 40764–40770, 2003.

[72] M. Jalkanen, A. Rapraeger, S. Saunders, and M. Bernfield, “Cell surface proteoglycan of mouse mammary epithelial cells is shed by cleavage of its matrix-binding ectodomain from its membrane-associated domain,” *The Journal of Cell Biology*, vol. 105, no. 6, pp. 3087–3096, 1987.

[73] V. C. Ramani, P. S. Pruett, C. A. Thompson, L. D. DeLucas, and R. D. Sanderson, “Heparan sulfate chains of syndecan-1 regulate ectodomain shedding,” *The Journal of Biological Chemistry*, vol. 287, no. 13, pp. 9952–9961, 2012.

[74] K. Ding, M. Lopez-Burks, J. A. Sánchez-Duran, M. Korc, and A. D. Lander, “Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells,” *The Journal of Cell Biology*, vol. 171, no. 4, pp. 729–738, 2005.

[75] Y. Yang, V. MacLeod, H.-Q. Miao et al., “Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis,” *The Journal of Biological Chemistry*, vol. 282, no. 18, pp. 13326–13333, 2007.

[76] K. Mahtouk, D. Hose, P. Raynaud et al., “Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma,” *Blood*, vol. 109, no. 11, pp. 4914–4923, 2007.

[77] A. Purushothaman, L. Chen, Y. Yang, and R. D. Sanderson, “Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma,” *The Journal of Biological Chemistry*, vol. 283, no. 47, pp. 32628–32636, 2008.

[78] L. Fux, N. Ilan, R. D. Sanderson, and I. Vlodavsky, “Heparanase: busy at the cell surface,” *Trends in Biochemical Sciences*, vol. 34, no. 10, pp. 511–519, 2009.

[79] K. Hayashida, P. D. Stahl, and W. P. Pyong, “Syndecan-1 ectodomain shedding is regulated by the small GTPase Rab5,” *The Journal of Biological Chemistry*, vol. 283, no. 51, pp. 35435–35444, 2008.

[80] V. L. Ott and A. C. Rapraeger, “Tyrosine phosphorylation of syndecan-1 and -4 cytoplasmic domains in adherent B82 fibroblasts,” *The Journal of Biological Chemistry*, vol. 273, no. 52, pp. 35291–35298, 1998.

[81] M. L. Fitzgerald, Z. Wang, P. W. Park, G. Murphy, and M. Bernfield, “Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase,” *The Journal of Cell Biology*, vol. 148, no. 4, pp. 811–824, 2000.

[82] V. C. Ramani and R. D. Sanderson, “Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse,” *Matrix Biology*, vol. 35, pp. 215–222, 2014.

[83] X. Wang, D. Zuo, Y. Chen et al., “Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer,” *British Journal of Cancer*, vol. 111, no. 10, pp. 1965–1976, 2014.

[84] M. D. Bass, M. R. Morgan, and M. J. Humphries, “Syndecans shed their reputation as inert molecules,” *Science Signaling*, vol. 2, no. 64, article pe18, 2009.

[85] M. D. Stewart, V. C. Ramani, and R. D. Sanderson, “Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk,” *The Journal of Biological Chemistry*, vol. 290, no. 2, pp. 941–949, 2015.

[86] V. Nikolova, C.-Y. Koo, S. A. Ibrahim et al., “Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression,” *Carcinogenesis*, vol. 30, no. 3, pp. 397–407, 2009.

[87] V. C. Ramani, Y. Yang, Y. Ren, L. Nan, and R. D. Sanderson, “Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity,” *The Journal of Biological Chemistry*, vol. 286, no. 8, pp. 6490–6499, 2011.

[88] T. Maeda, J. Desouky, and A. Friedl, “Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis,” *Oncogene*, vol. 25, no. 9, pp. 1408–1412, 2006.

[89] E. D. Hay, “An overview of epithelio-mesenchymal transformation,” *Acta Anatomica*, vol. 154, no. 1, pp. 8–20, 1995.

[90] R. Kalluri and R. A. Weinberg, “The basics of epithelial-mesenchymal transition,” *The Journal of Clinical Investigation*, vol. 119, no. 6, pp. 1420–1428, 2009.

[91] M. Kato, S. Saunders, H. Nguyen, and M. Bernfield, “Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells,” *Molecular Biology of the Cell*, vol. 6, no. 5, pp. 559–567, 1995.

[92] D. Sun, K. R. McAlmon, J. A. Davies, M. Bernfield, and E. D. Hay, “Simultaneous loss of expression of syndecan-1 and E-cadherin in the embryonic palate during epithelial-mesenchymal transformation,” *International Journal of Developmental Biology*, vol. 42, no. 5, pp. 733–736, 1998.

[93] C. E. Poblete, J. Fulla, M. Gallardo et al., “Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancer,” *International Journal of Oncology*, vol. 44, no. 3, pp. 647–654, 2014.

[94] I. B. Bayer-Garner and B. R. Smoller, “The expression of syndecan-1 is preferentially reduced compared with that of E-cadherin in anaplastic squamous cell carcinoma,” *Journal of Cutaneous Pathology*, vol. 28, no. 2, pp. 83–89, 2001.

[95] R. M. Day, X. Hao, M. Ilyas, P. Daszak, I. C. Talbot, and A. Forbes, “Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence,” *Virchows Archiv*, vol. 434, no. 2, pp. 121–125, 1999.

[96] H. R. Contreras, R. A. Ledezma, J. Vergara et al., “The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and β-catenin, in prostate cancer,” *Urologic Oncology*, vol. 28, no. 5, pp. 534–540, 2010.

[97] U. Brockstedt, K. Dobra, M. Nurminen, and A. Hjerpe, “Immunoreactivity to cell surface syndecans in cytoplasm and nucleus: tubulin-dependent rearrangements,” *Experimental Cell Research*, vol. 274, no. 2, pp. 235–245, 2002.

[98] L. Chen and R. D. Sanderson, “Heparanase regulates levels of syndecan-1 in the nucleus,” *PLoS ONE*, vol. 4, no. 3, Article ID e9497, 2009.

[99] K. Chen and K. J. Williams, “Molecular mediators for raft-dependent endocytosis of syndecan-1, a highly conserved, multifunctional receptor,” *The Journal of Biological Chemistry*, vol. 288, no. 20, pp. 13988–13999, 2013.

[100] F. Zong, E. Fthenou, N. Wolmer et al., “Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells,” *PLoS ONE*, vol. 4, no. 10, Article ID e7346, 2009.
nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype," *The Journal of Biological Chemistry*, vol. 286, no. 35, pp. 30377–30383, 2011.

[102] J. A. Buczek-Thomas, E. Hsia, C. B. Rich, J. A. Foster, and M. A. Nugent, "Inhibition of histone acetyltransferase by glycosaminoglycans," *Journal of Cellular Biochemistry*, vol. 105, no. 1, pp. 108–120, 2008.

[103] I. Kovalszky, J. Dudás, I. Oláh-Nagy et al., "Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor," *Molecular and Cellular Biochemistry*, vol. 183, no. 1-2, pp. 11–23, 1998.

[104] S. J. Busch, G. A. Martin, R. L. Barnhart, M. A. Cardin, and R. L. Jackson, "Trans-repressor activity of nuclear glycosaminoglycans on Fos and Jun/AP-1 oncprotein-mediated transcription," *Journal of Cell Biology*, vol. 116, no. 1, pp. 31–42, 1992.

[105] J. Dudás, G. Ramadori, T. Knittel et al., "Effect of heparin and liver heparan sulphate on interaction of HepG2-derived transcription factors and their cis-acting elements: altered potential of hepatocellular carcinoma heparan sulphate," *Biochemical Journal*, vol. 350, part 1, pp. 245–251, 2000.

[106] M. D. Stewart and R. D. Sanderson, "Heparan sulfate in the nucleus and its control of cellular functions," *Matrix Biology*, vol. 35, pp. 56–59, 2014.

[107] E. Hsia, T. P. Richardson, and M. A. Nugent, "Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling," *Journal of Cellular Biochemistry*, vol. 88, no. 6, pp. 1214–1225, 2003.

[108] N. Quarto and F. Amalric, "Heparan sulfate proteoglycans as transducers of FGF-2 signalling," *Journal of Cell Science*, vol. 107, part 11, pp. 3201–3212, 1994.

[109] F. Amalric, G. Bouche, H. Bonnet et al., "Fibroblast growth factor-2 (FGF-2) in the nucleus: translocation process and targets," *Biochemical Pharmacology*, vol. 47, no. 1, pp. 111–115, 1994.

[110] A. Wittrup, S.-H. Zhang, G. B. ten Dam et al., "ScFv antibody-induced translocation of cell-surface heparan sulfate proteoglycan to endocytic vesicles: evidence for heparan sulfate epitope specificity and role of both syndecan and glypicican," *Journal of Biological Chemistry*, vol. 284, no. 47, pp. 32959–32967, 2009.

[111] H. C. Christianson and M. Belting, "Heparan sulfate proteoglycan as a cell-surface endocytosis receptor," *Matrix Biology*, vol. 35, pp. 51–55, 2014.

[112] T. Letoha, A. Keller-Pintér, E. Kusz et al., "Cell-penetrating peptide exploited syndecans," *Biochimica et Biophysica Acta (BBA)—Biomembranes*, vol. 1798, no. 12, pp. 2258–2265, 2010.

[113] H. C. Christianson, K. J. Svensson, T. H. van Kuppevelt, J.-P. Li, and M. Belting, "Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 43, pp. 17380–17385, 2013.

[114] R. K. Margolis, C. P. Crockett, W.-L. Kiang, and R. U. Margolis, "Glycosaminoglycans and glycoproteins associated with rat brain nuclei," *Biochimica et Biophysica Acta*, vol. 451, no. 2, pp. 465–469, 1976.

[115] M. Ishihara, N. S. Fedarko, and H. E. Conrad, "Transport of heparan sulfate into the nuclei of hepatocytes," *Journal of Biological Chemistry*, vol. 261, no. 29, pp. 13575–13580, 1986.

[116] N. S. Fedarko and H. E. Conrad, "A unique heparan sulfate in the nuclei of hepatocytes: structural changes with the growth state of the cells," *Journal of Cell Biology*, vol. 102, no. 2, pp. 587–599, 1986.

[117] F. Cheng, P. Petersson, Y. Arroyo-Yanguas, and G. Westergren-Thorsson, "Differences in the uptake and nuclear localization of anti-proliferative heparan sulfate between human lung fibroblasts and human lung carcinoma cells," *Journal of Cellular Biochemistry*, vol. 83, no. 4, pp. 597–606, 2001.

[118] K. Dobra, M. Nurminen, and A. Hjerpe, "Growth factors regulate the expression profile of their syndecan co-receptors and the differentiation of mesothelioma cells," *Anticancer Research*, vol. 23, no. 3B, pp. 2435–2444, 2003.

[119] N. S. Fedarko, M. Ishihara, and H. E. Conrad, "Control of cell division in hepatoma cells by exogenous heparan sulfate proteoglycan," *Journal of Cellular Physiology*, vol. 139, no. 2, pp. 287–294, 1989.

[120] M. Roghani and D. Moscatelli, "Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms," *The Journal of Biological Chemistry*, vol. 267, no. 31, pp. 22156–22162, 1992.

[121] F. Zong, E. Fthenou, F. Mundt et al., "Specific syndecan-1 domains regulate mesenchymal tumor cell adhesion, motility and migration," *Plos ONE*, vol. 6, no. 6, Article ID e14816, 2011.

[122] Y. H.-F. Teng, R. S. Aquino, and P. W. Park, "Molecular functions of syndecan-1 in disease," *Matrix Biology*, vol. 31, no. 1, pp. 3–16, 2012.

[123] A. Anttonen, P. Heikkilä, M. Kajanti, M. Jalkanen, and N. Konishi, "Syndecan-1 contributes to prostate cancer growth and angiogenesis in an endometrial cancer xenograft model," *International Journal of Gynecological Cancer*, vol. 20, no. 5, pp. 751–756, 2010.

[124] S. Kumar-Singh, W. Jacobs, K. Dhaene et al., "Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome," *Journal of Pathology*, vol. 186, no. 3, pp. 300–305, 1998.

[125] K. Shimada, S. Anai, T. Fujii, N. Tanaka, K. Fujimoto, and N. Konishi, "Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells," *The Journal of Pathology*, vol. 231, no. 4, pp. 495–504, 2013.

[126] J.-H. Oh, H.-S. Lee, S.-H. Park, H.-S. Ryu, and C. K. Min, "Syndecan-1 overexpression promotes tumor growth and angiogenesis in a glioblastoma xenograft model," *International Journal of Gynecological Cancer*, vol. 20, no. 5, pp. 751–756, 2010.

[127] S. Y. Kim, E. J. Choi, J. A. Yun et al., "Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases," *International Journal of Medical Sciences*, vol. 12, no. 2, pp. 92–99, 2015.

[128] Y. Hashimoto, M. Skacel, and J. C. Adams, "Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors," *BMC Cancer*, vol. 8, article 185, 2008.

[129] P. Mukunyadzi, K. Liu, E. Y. Hanna, J. Y. Suen, and C.-Y. Fan, "Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma," *Modern Pathology*, vol. 16, no. 8, pp. 796–801, 2003.

[130] Y. Ito, H. Yoshida, K. Nakano et al., "Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation," *Histopathology*, vol. 43, no. 2, pp. 157–164, 2003.
[131] T. Maeda, C. M. Alexander, and A. Friedl, “Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells,” Cancer Research, vol. 64, no. 2, pp. 612–621, 2004.

[132] D. Mennerich, A. Vogel, I. Klaman et al., “Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours,” European Journal of Cancer, vol. 40, no. 9, pp. 1373–1382, 2004.

[133] H. Joensuu, A. Anttonen, M. Eriksson et al., “Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer,” Cancer Research, vol. 62, no. 18, pp. 5210–5217, 2002.

[134] A. Anttonen, S. Leppä, T. Ruotsalainen, H. Alphän, K. Mattson, and H. Joensuu, “Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy,” Lung Cancer, vol. 41, no. 2, pp. 171–177, 2003.

[135] F. Mundt, G. Heidari-Hamedani, G. Nilsson, M. Metintas, A. Hjerpe, and K. Dobra, “Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies,” BioMed Research International, vol. 2014, Article ID 419853, 11 pages, 2014.

[136] I. B. Bayer-Garner, B. Dilday, R. D. Sanderson, and B. R. Smoller, “Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma,” The American Journal of Dermatopathology, vol. 22, no. 2, pp. 119–122, 2000.

[137] A. A. H. Omar, C. Haglund, S. Virolainen et al., “Epithelial and stromal syndecan-1 and -2 are distinctly expressed in oral and cutaneous squamous cell carcinomas,” Journal of Oral Pathology and Medicine, vol. 42, no. 5, pp. 389–395, 2013.

[138] H. Kurokawa, M. Zhang, S. Matsumoto et al., “Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma,” Journal of Oral Pathology and Medicine, vol. 35, no. 5, pp. 301–306, 2006.

[139] P. Inki, H. Joensun, R. Grenman, P. Klemi, and M. Jalkanen, “Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck,” British Journal of Cancer, vol. 70, no. 2, pp. 319–323, 1994.

[140] A. Anttonen, M. Kajanti, P. Heikkilä, M. Jalkanen, and H. Joensuu, “Syndecan-1 expression has prognostic significance in head and neck carcinoma,” British Journal of Cancer, vol. 79, no. 3-4, pp. 558–564, 1999.

[141] A. Anttonen, S. Leppä, P. Heikkilä, R. Grenman, and H. Joensuu, “Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations,” Journal of Cancer Research and Clinical Oncology, vol. 132, no. 7, pp. 451–457, 2006.

[142] J. O. Pulkkinen, M. Pelttinen, M. Jalkanen, P. Klemi, and R. Grénman, “Syndecan-1: a new prognostic marker in laryngeal cancer,” Acta Oto-Laryngologica, vol. 117, no. 2, pp. 312–315, 1997.

[143] C.-L. Chen and D.-L. Ou, “Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis,” Human Pathology, vol. 37, no. 10, pp. 1279–1285, 2006.

[144] X.-F. Hu, J. Yao, S.-G. Gao, Y.-T. Yang, X.-Q. Peng, and X.-S. Feng, “Midkine and syndecan-1 levels correlate with the progression of malignant gastric cardiac adenocarcinoma,” Molecular Medicine Reports, vol. 10, no. 3, pp. 1409–1415, 2014.

[145] J.-P. Wiksten, J. Lundin, S. Nordling et al., “Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer,” International Journal of Cancer, vol. 95, no. 1, pp. 1–6, 2001.

[146] Y.-Q. Chu, Z.-Y. Ye, H.-Q. Tao, Y.-Y. Wang, and Z.-S. Zhao, “Relationship between cell adhesion molecules expression and the biological behavior of gastric carcinoma,” World Journal of Gastroenterology, vol. 14, no. 13, pp. 1990–1996, 2008.

[147] J. Watari, Y. Saitoh, M. Fujiiya et al., “Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype,” Journal of Gastroenterology, vol. 39, no. 2, pp. 104–112, 2004.

[148] M. Lundin, S. Nordling, J. Lundin, J. Isola, J.-P. Wiksten, and C. Haglund, “Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer,” Oncology, vol. 68, no. 4–6, pp. 306–313, 2005.

[149] A. V. Suhovskih, S. V. Aidagulova, V. I. Kushba, and E. V. Grigorieva, “Proteoglycans as potential microenvironmental biomarkers for colon cancer,” Cell and Tissue Research, 2015.

[150] A. Matsumoto, M. Ono, Y. Fujimoto, R. L. Gallo, M. Bernfield, and Y. Kohgo, “Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential,” International Journal of Cancer, vol. 74, no. 5, pp. 482–491, 1997.

[151] J. R. Conejo, J. Kleeff, A. Kolipanos et al., “Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers,” International Journal of Cancer, vol. 88, no. 1, pp. 12–20, 2000.

[152] M. E. Lendorf, T. Manon-Jensen, P. Kronqvist, H. A. B. Mulhaupt, and J. R. Couchman, “Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma,” Journal of Histochemistry and Cytochemistry, vol. 59, no. 6, pp. 615–629, 2011.

[153] D. Loussouarn, L. Campion, C. Sagan et al., “Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas,” British Journal of Cancer, vol. 98, no. 12, pp. 1993–1998, 2008.

[154] K. Matsuda, H. Maruyama, F. Guo et al., “Glypican-1 is over-expressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells,” Cancer Research, vol. 61, no. 14, pp. 5562–5569, 2001.

[155] M. J. Stanley, M. W. Stanley, R. D. Sanderson, and R. Zera, “Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma,” The American Journal of Clinical Pathology, vol. 112, no. 3, pp. 377–383, 1999.

[156] M. Leivonen, J. Lundin, S. Nordling, K. von Boguslawski, and C. Haglund, “Prognostic value of syndecan-1 expression in breast cancer,” Oncology, vol. 67, no. 1, pp. 11–18, 2004.

[157] K. Tiemann, M. T. Weigel, I. Alkatout et al., “Significance of syndecan-1 expression in ductal carcinoma in situ of the breast,” Anticancer Research, vol. 34, no. 7, pp. 3607–3616, 2014.

[158] Y. Shinyo, J. Kodama, Hasengaowa, T. Kusumoto, and Y. Hiramatsu, “Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer,” Gynecologic Oncology, vol. 96, no. 3, pp. 776–783, 2005.

[159] E. J. Davies, F. H. Blackhall, J. H. Shanks et al., “Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer,” Clinical Cancer Research, vol. 10, no. 15, pp. 5178–5186, 2004.

[160] Hasengaowa, J. Kodama, T. Kusumoto, Y. Shinyo, N. Seki, and Y. Hiramatsu, “Prognostic significance of syndecan-1 expression in human endometrial cancer,” Annals of Oncology, vol. 16, no. 7, pp. 1109–1115, 2005.

[161] A. V. Suhovskih, L. A. Mostovich, I. S. Kunin et al., “Proteoglycan expression in normal human prostate tissue and prostate cancer,” ISRN Oncology, vol. 2013, Article ID 680136, 9 pages, 2013.
[162] J. H. Kim and J. Park, “Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer,” Human Pathology, vol. 45, no. 9, pp. 1830–1838, 2014.

[163] T. Szarvas, H. Reis, G. Kramer et al., “Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer,” Human Pathology, vol. 45, no. 4, pp. 674–682, 2014.

[164] J. Hata, M. Kripnerova, J. Tukova et al., “Tumour-stroma interactions in urothelial cancer,” Der Urologe A, vol. 54, no. 4, pp. 516–525, 2015.

[165] C. Seidel, A. Sundan, M. Hjorth et al., “Serum syndecan-1: an independent prognostic marker in multiple myeloma,” Blood, vol. 95, no. 2, pp. 388–392, 2000.

[166] S. Dinner, W. Witteles, R. Witteles et al., “The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis,” British Journal of Haematology, vol. 161, no. 3, pp. 367–372, 2013.

[167] Y. Yang, S. Yaccoby, W. Liu et al., “Soluble syndecan-1 promotes growth of myeloma tumors in vivo,” Blood, vol. 100, no. 2, pp. 610–617, 2002.

[168] I. B. Bayer-Garner, R. D. Sanderson, M. V. Dhodapkar, R. B. Owens, and C. S. Wilson, “Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions,” Modern Pathology, vol. 14, no. 10, pp. 1052–1058, 2001.

[169] R. Gharbaran, A. Goy, T. Tanaka et al., “Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients,” Journal of Hematology & Oncology, vol. 6, article 62, 2013.

[170] E. Toyoshima, Y. Ohsaki, Y. Nishigaki, Y. Fujimoto, Y. Kohgo, and K. Kikuchi, “Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor,” Journal of Neuro-Oncology, vol. 77, no. 1, pp. 25–32, 2006.